Sourced directly from manufacturers
Supported by UK-based clinical team with monthly check-ins
Access to Obesity Specialist Dietitian
Fully UK GPhC Registered Pharmacy, trusted by over 90,000 patients
Two oral GLP-1 treatments are generating the most excitement in the UK right now:
GLP-1 (glucagon-like peptide-1) receptor agonists are prescription medicines used in weight management. Some GLP-1 medicines are currently available as injections following assessment by a clinician.
Oral GLP-1 tablets are tablet formulations being developed and studied for weight management. These medicines work by mimicking the GLP-1 hormone, which can help regulate appetite and food intake.
Treatment suitability, availability and prescribing decisions are determined by a clinician following an appropriate consultation.
Tablet-based weight loss treatments
Contain a GLP-1 receptor agonist (the same active ingredient as Wegovy)
Taken once daily, rather than once weekly by injection
Clinically tested with results comparable to injectable options
A non-injectable alternative for those who prefer not to use a pen
Easier to fit into everyday life for some people
No refrigeration or injection equipment required
The same clinically-led approach, in a simpler format
Two large clinical trials give us the best picture so far. Here's what happened when real patients took oral GLP-1 tablets alongside diet and lifestyle support.
average body weight lost over 64 weeks
In a study of 307 adults – that's roughly 1 in 4 losing 20% or more of their body weight.
average body weight lost over 74 weeks
In a study of 3,127 adults – over half lost at least 10% of their body weight.
* Averages from clinical trials in controlled settings alongside diet and lifestyle support. Individual results will vary.
* The two trials used different designs and durations and cannot be directly compared with each other.
* Wegovy tablet is now available in the UK. Foundayo is not yet available in the UK.
Oral GLP-1 tablets and injectable GLP-1 treatments are both effective, clinically-proven options. The right choice depends on your personal preferences and circumstances. Here is a quick comparison:
* Averages from clinical trials in controlled settings alongside diet and lifestyle support. Individual results will vary.
* The two trials used different designs and durations and cannot be directly compared with each other.
* Wegovy tablet is now available in the UK. Foundayo is available for pre-order now with Phlo Clinic.
We will keep you informed with everything you need to know. Here is what being on our list means for you:
Be the first to know: whilst Wegovy tablets are now available, we'll make sure you get notified the moment orforglipron is licensed for use in the UK.
Clinician-led care: as with all Phlo Clinic treatments, you will receive ongoing support from our UK-registered clinical team
No need to keep checking: we will do the monitoring and reach out when there is a meaningful update
Trusted by thousands of patients: Phlo Clinic is a GPhC-regulated pharmacy
Expert guidance: our clinicians will help you understand whether oral GLP-1 treatment is right for you
Like all medicines, oral GLP-1 tablets can cause side effects. Most are digestive and tend to be mild to moderate, often settling down as your body adjusts during the first few weeks of treatment.
*This information is based on phase 3 clinical trial data and US prescribing information.
This is not a complete list of side effects. Always consult a qualified clinician before starting treatment.
Our clinical team have been closely following developments in oral GLP-1 research. Here are the latest articles from the Phlo Clinic weight loss advice hub:
1. Wharton S, et al. Oral semaglutide 25mg in adults with overweight or obesity (OASIS 4). N Engl J Med. 2025;393(11):1077–1087. doi:10.1056/NEJMoa2500969
2. Wharton S, et al. Orforglipron, an oral GLP-1 receptor agonist for obesity (ATTAIN-1). N Engl J Med. 2025;393(18):1796–1806. doi:10.1056/NEJMoa2511774
3. Novo Nordisk. Wegovy (semaglutide) tablet US prescribing information. Plainsboro, NJ: Novo Nordisk Inc.; 2025. 4.Eli Lilly and Company. Foundayo (orforglipron) US prescribing information. Indianapolis, IN: Eli Lilly; 2026.
4. Eli Lilly and Company. Foundayo (orforglipron) US prescribing information. Indianapolis, IN: Eli Lilly; 2026.